Nuvectis Pharma(US:NVCT) Globenewswireยท2025-10-16 12:00Core Insights - Nuvectis Pharma, Inc. is set to present its clinical findings on NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston from October 22-26, 2025 [1] Group 1: Company Overview - Nuvectis Pharma, Inc. focuses on developing innovative precision medicines for serious unmet medical needs in oncology [3] - The lead program, NXP900, is an oral small molecule inhibitor targeting SRC Family of Kinases (SFK), including SRC and YES1, with a unique mechanism that inhibits both catalytic and scaffolding functions [3] - NXP900 has completed a Phase 1a dose escalation study and is currently being evaluated in a Phase 1b program [3] Group 2: Upcoming Presentations - The first poster presentation will cover clinical safety, pharmacokinetics, pharmacodynamics, and cytochrome P450 interactions for NXP900, presented by Gerald Falchook, MD, on October 23, 2025, from 12:30 to 4 pm ET [2] - The second poster presentation will focus on the efficacy of NXP900 in inhibiting tumor growth in FAT1 mutated xenograft models, presented by Asier Unciti-Broceta on the same date and time [2]